<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456312</url>
  </required_header>
  <id_info>
    <org_study_id>ML25588</org_study_id>
    <nct_id>NCT01456312</nct_id>
  </id_info>
  <brief_title>HBsAg Related Response Guided Therapy</brief_title>
  <acronym>S-RGT</acronym>
  <official_title>A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: Compare Pegasys RGT overall response rate (i.e., HBeAg seroconversion
      rate) with Pegasys mono historical response rate at week 72 (48 week treatment with 24 week
      follow up)

      Secondary objective :

        -  The changes of HBsAg titer

             -  The rate of combined HBeAg seroconversion and HBV DNA &lt; 300 copies/mL ⅲ. The rate
                of serum HBV DNA &lt; 300 copies/mL

                  -  The rate of ALT normalization ⅴ. The rate of HBsAg loss ⅵ. The rate of serum
                     HBV DNA &lt; 10,000 copies/mL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 12w treatment of Pegasys, depends on results of quantitative HBsAg test, Patients will
      be allocated to one of three groups.

        -  HBsAg &gt;20,000 : study termination

        -  Group A :1,500&lt;HBsAg≤ 20,000

        -  Group B : .HBsAg ≤ 1500 At week 48, according to HbeAg seroconversion, patients will be
           allocated to one of two sub-groups(A-1, A-2, B-1, B-2) Patients are seen for evaluation
           at treatment weeks 4,8,12,24,36,48. Post-treatment assessments will be performed at 4,12
           and 24 week during off-treatment phase for the assessment of the primary and main
           secondary endpoints of the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>24 weeks post treatment follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of HBsAg titer</measure>
    <time_frame>baseline and 24weeks post treatment follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>HBsAg quantification&gt;20,000 IU/ml</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>stop peginterferon alfa 2a if patients reach HBsAg quantification&gt;20,000 Iu/ml at 12w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBsAg&lt;=1500IU/ml</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>extend peginterferon alfa 2a until 48weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBsAg &gt;1500 &lt;=20,000 IU/ML</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Duration and combination</description>
    <arm_group_label>HBsAg quantification&gt;20,000 IU/ml</arm_group_label>
    <arm_group_label>HBsAg&lt;=1500IU/ml</arm_group_label>
    <arm_group_label>HBsAg &gt;1500 &lt;=20,000 IU/ML</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>combination</description>
    <arm_group_label>HBsAg &gt;1500 &lt;=20,000 IU/ML</arm_group_label>
    <other_name>Baraclude Tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Positive HBsAg for more than 6 months, positive HBeAg, detectable HBV DNA(patients
             must have &gt; 100,000 copies/ml as measured by PCR) and anti-HBs negative

          3. Elevated serum ALT &gt; 2ULN but ≤ 10 × ULN as determined by two abnormal values taken ≥
             14 days apart during the six months before the first dose of study drug with at least
             one of the determinations obtained ≤ 35 days prior to the first dose.

        Exclusion Criteria:

          1. Patients must not have received antiviral therapy for their chronic hepatitis B.
             Patients who are expected to need systemic antiviral therapy other than that provided
             by the study at any time during their participation in the study are also excluded.
             Exception: patients who have had less than 6 months treatment of NA(Nucleos(t)ide
             analog) and more than 1 year wash-out period for systemic antiviral therapy and
             negative results in the NA resistance test at baseline are not excluded.

          2. Positive test at screening for HAV IgM Ab, HCV-RNA or HCV Ab, HDV Ab or HIV Ab.

          3. Diagnosed hepatic cellular carcinoma

          4. Any evidence of decompensated liver disease (Childs B-C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwansik Lee, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwansik Lee, professor</last_name>
    <phone>+82 11 9636 9935</phone>
    <email>leeks519@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shinchon Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120742</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanghoon Ahn, professor</last_name>
      <phone>82-2-2228-1936</phone>
      <email>ahnsh@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Sanhoon Ahn, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>October 29, 2012</last_update_submitted>
  <last_update_submitted_qc>October 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Kwan Sik Lee</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Peginterferon alfa 2a</keyword>
  <keyword>Entecavir</keyword>
  <keyword>Response Guided Therapy</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

